These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 27460163

  • 1. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
    Pavord ID, Lettis S, Anzueto A, Barnes N.
    Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
    [Abstract] [Full Text] [Related]

  • 2. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 3. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [Abstract] [Full Text] [Related]

  • 4. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM.
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL, Lin CH.
    Int J Chron Obstruct Pulmon Dis; 2016 May; 11():2341-2348. PubMed ID: 27703344
    [Abstract] [Full Text] [Related]

  • 6. The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world.
    Barnes N, Ishii T, Hizawa N, Midwinter D, James M, Hilton E, Jones PW.
    Int J Chron Obstruct Pulmon Dis; 2018 May; 13():433-440. PubMed ID: 29440882
    [Abstract] [Full Text] [Related]

  • 7. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 8. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.
    Cheng SL.
    Int J Chron Obstruct Pulmon Dis; 2018 May; 13():2775-2784. PubMed ID: 30233168
    [Abstract] [Full Text] [Related]

  • 9. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
    Oshagbemi OA, Franssen FME, van Kraaij S, Braeken DCW, Wouters EFM, Maitland-van der Zee AH, Driessen JHM, de Vries F.
    COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
    [Abstract] [Full Text] [Related]

  • 10. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
    Oshagbemi OA, Odiba JO, Daniel A, Yunusa I.
    Curr Drug Targets; 2019 Apr; 20(16):1670-1679. PubMed ID: 31393244
    [Abstract] [Full Text] [Related]

  • 11. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
    Barnes NC, Sharma R, Lettis S, Calverley PM.
    Eur Respir J; 2016 May; 47(5):1374-82. PubMed ID: 26917606
    [Abstract] [Full Text] [Related]

  • 12. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
    Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, Schofield P, Armstrong D, White P.
    Respir Res; 2020 Jan 03; 21(1):3. PubMed ID: 31900184
    [Abstract] [Full Text] [Related]

  • 13. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.
    Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.
    Am J Respir Crit Care Med; 2017 May 01; 195(9):1189-1197. PubMed ID: 28278391
    [Abstract] [Full Text] [Related]

  • 14. Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease.
    Pascoe SJ, Papi A, Midwinter D, Lettis S, Barnes N.
    Respir Res; 2019 Aug 23; 20(1):195. PubMed ID: 31443653
    [Abstract] [Full Text] [Related]

  • 15. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis.
    Hinds DR, DiSantostefano RL, Le HV, Pascoe S.
    BMJ Open; 2016 Jun 01; 6(6):e010099. PubMed ID: 27251682
    [Abstract] [Full Text] [Related]

  • 16. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
    Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, Barr RG, Carretta EE, Couper DJ, Cooper CB, Hoffman EA, Kanner RE, Kleerup E, O'Neal WK, Paine R, Peters SP, Alexis NE, Woodruff PG, Han MK, Meyers DA, Bleecker ER, SPIROMICS investigators.
    Lancet Respir Med; 2017 Dec 01; 5(12):956-967. PubMed ID: 29146301
    [Abstract] [Full Text] [Related]

  • 17. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, Makulova N, Shih VH, Brooks L, Barker P, Martin UJ, Newbold P.
    Lancet Respir Med; 2020 Feb 01; 8(2):158-170. PubMed ID: 31575508
    [Abstract] [Full Text] [Related]

  • 18. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
    Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.
    Respir Res; 2018 Oct 05; 19(1):196. PubMed ID: 30290801
    [Abstract] [Full Text] [Related]

  • 19. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J, SUMMIT investigators.
    Respir Med; 2017 Oct 05; 131():27-34. PubMed ID: 28947039
    [Abstract] [Full Text] [Related]

  • 20. Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD.
    Cheng SL, Wang HH, Lin CH.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 05; 12():2231-2238. PubMed ID: 28814851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.